Who owns TSCAN THERAPEUTICS INC?
- Ticker: TCRX
- CUSIP Number: 89854m101
Tip: Access positions for across all investors
Analyze quarterly positions in Tscan Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Tscan Therapeutics stock
Who bought or sold TSCAN THERAPEUTICS INC this quarter?
Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
---|---|---|---|---|---|
Lynx1 Capital Management | 5.2M | $31M | 0% | Jun 2024 |
|
EcoR1 Capital | 5.0M | $29M | 0% | Jun 2024 |
|
BlackRock | 4.5M | $26M | 163% | Jun 2024 |
|
BVF | 3.0M | $18M | 0% | Jun 2024 |
|
Baker Bros. Advisors | 2.8M | $16M | 0% | Jun 2024 |
|
Vanguard Group | 2.1M | $13M | 18% | Jun 2024 |
|
Propel Bio Management | 2.1M | $12M | 0% | Jun 2024 |
|
Deer Management | 1.2M | $7.3M | 0% | Jun 2024 |
|
Alphabet | 1.1M | $6.3M | 0% | Jun 2024 |
|
Simplify Asset Management | 1.0M | $5.2M | 0% | Sep 2024 |
|
Dr. Jeffrey R. Jay, M.D. | 941k | $5.5M | 100% | Jun 2024 |
|
Geode Capital Management | 901k | $5.3M | 118% | Jun 2024 |
|
Stempoint Capital | 845k | $4.9M | 100% | Jun 2024 |
|
LMR Partners | 666k | $3.9M | 100% | Jun 2024 |
|
DC Funds | 630k | $3.7M | 0% | Jun 2024 |
|
State Street Corporation | 608k | $3.6M | 350% | Jun 2024 |
|
Invesco | 500k | $2.9M | 2% | Jun 2024 |
|
Standard Life Aberdeen | 372k | $1.9M | 27% | Sep 2024 |
|
Paradigm Biocapital Advisors | 354k | $2.1M | 100% | Jun 2024 |
|
Marshall Wace | 308k | $1.8M | 61% | Jun 2024 |
|
Morgan Stanley | 242k | $1.4M | 8% | Jun 2024 |
|
Tocqueville Asset Management | 210k | $1.2M | -1% | Jun 2024 |
|
Woodline Partners | 164k | $956k | 100% | Jun 2024 |
|
Citadel Advisors | 158k | $924k | 1282% | Jun 2024 |
|
Alpine Partners VI | 138k | $804k | 100% | Jun 2024 |
|
Bank of New York Mellon | 117k | $682k | 100% | Jun 2024 |
|
Charles Schwab Investment Management | 113k | $661k | 411% | Jun 2024 |
|
Jane Street | 99k | $579k | -35% | Jun 2024 |
|
Stifel Financial | 95k | $558k | -6% | Jun 2024 |
|
Troluce Capital Advisors | 93k | $543k | 100% | Jun 2024 |
|
NewEdge Wealth | 92k | $535k | 0% | Jun 2024 |
|
Renaissance Technologies | 80k | $468k | 70% | Jun 2024 |
|
Qube Research & Technologies | 78k | $459k | -45% | Jun 2024 |
|
Brown Brothers Harriman & Co. | 76k | $445k | 100% | Jun 2024 |
|
Nuveen Asset Management | 70k | $409k | 100% | Jun 2024 |
|
Laurion Capital Management | 60k | $353k | -83% | Jun 2024 |
|
American Century Companies | 48k | $278k | 49% | Jun 2024 |
|
Rhumbline Advisers | 47k | $274k | 100% | Jun 2024 |
|
Bank of America Corporation | 44k | $256k | 45% | Jun 2024 |
|
Bridgeway Capital Management | 38k | $224k | -39% | Jun 2024 |
|
Dean Capital Investments Management | 36k | $208k | 0% | Jun 2024 |
|
Goldman Sachs Group | 35k | $206k | -86% | Jun 2024 |
|
Millennium Management | 28k | $163k | -93% | Jun 2024 |
|
Pale Fire Capital SE | 22k | $126k | 0% | Jun 2024 |
|
Letko, Brosseau & Associates | 21k | $121k | 0% | Jun 2024 |
|
Deutsche Bank Aktiengesellschaft | 21k | $121k | 100% | Jun 2024 |
|
Squarepoint Ops | 19k | $113k | 100% | Jun 2024 |
|
Man Group | 19k | $109k | -76% | Jun 2024 |
|
Jpmorgan Chase & Co | 16k | $96k | -76% | Jun 2024 |
|
SG Americas Securities | 16k | $78k | 100% | Sep 2024 |
|
Manufacturers Life Insurance Company | 15k | $90k | 100% | Jun 2024 |
|
Wells Fargo & Company | 14k | $81k | 4438% | Jun 2024 |
|
Ing Investment Management | 14k | $80k | 100% | Jun 2024 |
|
Marathon Trading Investment Management | 14k | $80k | -73% | Jun 2024 |
|
Barclays | 13k | $77k | 100% | Jun 2024 |
|
T. Rowe Price Associates | 12k | $0 | 100% | Jun 2024 |
|
Dimensional Fund Advisors | 12k | $70k | 100% | Jun 2024 |
|
Jump Financial | 11k | $63k | 5% | Jun 2024 |
|
CornerCap Investment Counsel | 11k | $54k | -53% | Sep 2024 |
|
MetLife Investment Advisors | 10k | $60k | 100% | Jun 2024 |
|
Waldron | 10k | $50k | 0% | Sep 2024 |
|
Aries Wealth Management | 10k | $50k | 0% | Sep 2024 |
|
Citigroup | 8.4k | $49k | -93% | Jun 2024 |
|
New York State Common Retirement Fund | 6.2k | $31k | -69% | Sep 2024 |
|
Us Bancorp | 4.5k | $22k | 100% | Sep 2024 |
|
Tower Research Capital | 4.2k | $25k | 100% | Jun 2024 |
|
Summit Investment Advisors | 3.8k | $22k | 100% | Jun 2024 |
|
California State Teachers Retirement System | 2.8k | $16k | 100% | Jun 2024 |
|
Amalgamated Bank | 1.3k | $7.0k | 0% | Sep 2024 |
|
Lazard Asset Management | 176.00 | $0 | -93% | Jun 2024 |
|
GAMMA Investing | 142.00 | $707.003800 | 100% | Sep 2024 |
|
NISA Investment Advisors | 121.00 | $603.003500 | 100% | Sep 2024 |
|
Atlas Capital Advisors | 18.00 | $88.999200 | 0% | Sep 2024 |
|
CWM | 7.00 | $0 | 100% | Sep 2024 |
|
Capital Advisors | 2.00 | $0 | 100% | Sep 2024 |
|
Who sold out of Tscan Therapeutics?
Fund or Company Name | Date Sold | Shares Held | Valued At |
---|---|---|---|
Susquehanna International | Mar 2024 | 298k | $2.4M |
Cubist Systematic Strategies | Mar 2024 | 44k | $352k |
Balyasny Asset Management | Mar 2024 | 42k | $333k |
Two Sigma Investments | Mar 2024 | 38k | $300k |
Hrt Financial | Mar 2024 | 35k | $276k |
Brevan Howard Capital Management | Mar 2024 | 35k | $275k |
Y-Intercept | Mar 2024 | 24k | $194k |
Point72 Asia | Mar 2024 | 20k | $157k |
OMERS Administration Corporation | Mar 2024 | 14k | $113k |
Leucadia National Corporation | Mar 2024 | 12k | $97k |
Privium Fund Management | Jun 2024 | 12k | $69k |
CTC Alternative Strategies | Mar 2024 | 11k | $87k |
Macquarie Group | Mar 2024 | 1.6k | $12.944000 |
Federated Investors | Mar 2024 | 56.00 | $444.998400 |